Need help or have questions about your order? Call 510-991-8265Questions about your order? Call 510-991-8265

Sign InShop GLPs
Shop GLPs

CJC-1295 Side Effects: Serious Adverse Events

By
Published Updated Last reviewed
10 linked public sourcesEditorial, sourcing, and corrections policy

HealthRX.com

Serious events cited for CJC-1295 and what remains unknown

Print or save as PDF

At a glance

  • Approval status / Not approved in any country FDA searched [2]
  • Human studies / Three published, all the DAC form, all in healthy volunteers [2]
  • Serious events cited by FDA / Increased heart rate, systemic vasodilatory reaction [1]
  • Trial death / Phase 2 HIV lipodystrophy trial (192 enrolled) ended in 2006; role of the drug unknown [2]
  • Growth hormone class risks / Glucose intolerance, fluid retention, tumor growth concerns [2]
  • Half-life after one injection / 5.8 to 8.1 days [3]

What serious adverse events are actually documented for CJC-1295?

Two things stand out, and they are different in kind.

FDA's compounding-safety page lists concerns about CJC-1295 that include possible immunogenicity for certain routes of administration, impurity and characterization problems, and "serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction" [1]. Separately, a phase 2 trial was stopped in 2006 after a participant died [2].

The peptide once sat in FDA's category 2 of bulk substances that may present significant safety risks. It now appears in the "nominated but withdrawn" table because the nominators withdrew their nominations. FDA's stated safety concerns are still on the page [1].

Questions worth asking

Choose the questions you want to keep

The 2006 death in the HIV lipodystrophy trial

ConjuChem withdrew CJC-1295 DAC from clinical trials in 2006 after a participant in a phase 2 trial in HIV lipodystrophy, which enrolled 192 people, died [2].

Per FDA's account of anecdotal news reports, the person had chest discomfort 2 hours after an 11th weekly dose, an ECG showed an acute heart attack, and the attending physician considered undiagnosed coronary artery disease with plaque rupture the most likely explanation [2]. The trial data were never published, so a role for CJC-1295 cannot be confirmed or ruled out [2].

Heart rate and blood pressure changes

In Ionescu and Frohman 2006, healthy men aged 20 to 40 received one injection of 60 or 90 micrograms/kg. No serious adverse events occurred, and dose-dependent increases in heart rate and transient injection-site redness and tenderness were reported [2].

The growth hormone risk behind the warning

FDA's stated concern is that raising growth hormone and IGF-I carries the risks listed on approved growth hormone labels, for example glucose intolerance and diabetes, fluid retention, and tumor growth concerns [2].

The exposure is not brief. In Teichman 2006, after a single subcutaneous injection of CJC-1295 DAC, the estimated half-life was 5.8 to 8.1 days, mean plasma GH rose 2- to 10-fold for 6 days or more, and mean IGF-I rose 1.5- to 3-fold for 9 to 11 days. After multiple doses, mean IGF-I stayed above baseline for up to 28 days [3].

Ionescu and Frohman found something similar. One week after a single injection, GH pulse frequency and size were unchanged, while trough GH rose about 7.5-fold, mean GH rose 46% and IGF-I rose 45% [4].

Dr Ashley Froese on cancer risk from growth-hormone peptides

Dr. Ashley Froese argues that peptides which raise growth hormone also raise insulin-like growth factor, and that chronically high levels of this factor are linked with a modestly higher relative risk of cancers such as breast, prostate, colon and pancreatic. In her view this is correlation rather than proven causation, so no one has shown that peptide therapy grows cancers. She says the concern lies mostly in chronic, sustained elevation rather than the natural pulsing of growth hormone during sleep. She notes that screening tools are not yet good enough to catch hidden cancers, so she thinks people should understand the risk and doctors should discuss it openly rather than shutting the conversation down.

Who is speaking?

Dr. Ashley Froese. Board-certified primary-care physician and direct primary care clinic runner, as described on the channel and in the video description Background

Episode notes and full video

What the human studies did report

In the two Teichman 2006 trials, per FDA's summary: injection-site reactions in about 70% of treated subjects in study 1 and in all treated subjects in study 2; headache in 63% versus 14% on placebo in study 1; flushing, warmth and transient low blood pressure in about 30% of treated subjects in study 1; transient diarrhea; and transient dizziness and low blood pressure in two subjects. Most events were more common at the higher doses of 125 or 250 micrograms/kg, and no serious adverse reactions were reported [2][3]. The authors called it relatively well tolerated, particularly at 30 or 60 micrograms/kg [3].

What people on Reddit report

Accounts from people using a CJC blend with ipamorelin, describing flushing, sleep, heart rate and tiredness after doses. These are self-reports, not trial data.

tjbarker85 · Peptidesource

Flushed face and accelerated heart rate is pretty normal with cjc. Never had any reaction in my throat though

Says a flushed face and faster heart rate are common with this peptide, but a throat reaction was not something they had.

Read the source discussion

HNuJDL · Biohackers

It disturbs my sleep significantly. My heart rate is noticeably higher than normal at night.

Reports poor sleep and a faster heart rate at night, which eased after moving the dose to the morning.

Read the source discussion

Dear_Science_6571 · Biohackers

I started with 200mc of each but I had to start halving that dose because its been making me to tired to function the next day.

Reports daytime fatigue that led them to cut the dose, and that the tiredness faded after a few days off.

Read the source discussion

How far the human data go

FDA said the human studies were short, small and mostly single-dose, so long-term safety is unknown, and it describes the available clinical data as limited [1][2]. All three were of the DAC form in healthy volunteers, and FDA found no study of any form of CJC-1295 in people with a disease [2].

What is actually being injected

No form of CJC-1295 is approved in any of the countries FDA searched, and none is authorized by the European Medicines Agency [2]. It is not on FDA's list of bulk substances for state-licensed pharmacies or its list for outsourcing facilities, it is not a component of an approved drug, and it has no USP monograph [5][6].

In December 2024 an FDA advisory committee voted 0 yes and 13 no on CJC-1295 free base, 1 yes and 12 no on CJC-1295 acetate, and 0 yes and 13 no on each of the three DAC forms [7]. Products sold online are mostly labeled 'research use only', including blends with ipamorelin, and research-use-only products are not approved drugs [2].

Check what you know

Think you have it? Try 5 quick questions and see what the article says.

1. According to Teichman 2006, how long was the estimated half-life after one subcutaneous injection of CJC-1295 DAC?

Question 1 of 5

Score: 0 right, 0 of 5 answered

Frequently asked questions

What is the most serious risk of CJC-1295?
FDA cites serious adverse events associated with CJC-1295 that include increased heart rate and systemic vasodilatory reaction [1]. A phase 2 trial of CJC-1295 DAC also ended in 2006 after a participant died [2].
Did anyone die in a CJC-1295 trial?
Yes. A participant died during a phase 2 trial of CJC-1295 DAC in HIV lipodystrophy, and the developer withdrew the drug from trials in 2006. The data were never published [2].
Can CJC-1295 cause cancer?
The published human studies ran for weeks in healthy volunteers, so they cannot answer a long-term question like this [2][3]. FDA raises tumor growth concerns, listing them among the risks carried on approved growth hormone labels for anything that elevates growth hormone and IGF-I [2].
Does CJC-1295 raise blood pressure?
The trial reports FDA summarized describe transient low blood pressure. In the first Teichman 2006 trial, flushing, warmth and transient low blood pressure occurred in about 30% of treated subjects [2]. FDA cites systemic vasodilatory reaction and increased heart rate among the serious adverse events associated with CJC-1295 [1].
How long do CJC-1295 effects last?
After one subcutaneous injection of CJC-1295 DAC, the estimated half-life was 5.8 to 8.1 days, mean plasma GH rose 2- to 10-fold for 6 days or more, and mean IGF-I rose 1.5- to 3-fold for 9 to 11 days [3]. After multiple doses, mean IGF-I stayed above baseline for up to 28 days [3].
Is CJC-1295 FDA approved?
No. FDA found no approved product containing any form of CJC-1295 in the countries it searched, and none authorized by the European Medicines Agency [2]. It is not on FDA's list of bulk substances for state-licensed pharmacies or for outsourcing facilities and has no USP monograph [5][6]. In December 2024 an FDA advisory committee voted against adding all five forms to the compounding list [7].

Reader questions

What people actually ask

Short answers drawn from the sources this article cites.

What side effects does CJC have?

The serious adverse events FDA cites for CJC-1295 are increased heart rate and systemic vasodilatory reaction. In human studies, injection-site reactions were most common, and headache, flushing, warmth, transient low blood pressure, transient diarrhea and dizziness were also reported. No serious adverse reactions were reported in those trials, and most events were more common at the higher doses of 125 or 250 micrograms/kg.

What are the negative side effects of peptides?

FDA's stated concern is that raising growth hormone and IGF-I carries the risks listed on approved growth hormone labels. These include glucose intolerance and diabetes, fluid retention, and tumor growth concerns. Long-term safety is unknown, because the human studies were short, small and mostly single-dose.

How safe is cjc+ipamorelin?

The safety picture is incomplete. CJC-1295 is not approved in any country FDA searched, and the human data come from three published studies of the DAC form in healthy volunteers. FDA found no study of any form in people with a disease. A phase 2 trial ended in 2006 after a participant died, and the data were never published, so a causal link is neither shown nor excluded.

References

Show all 10 referencesHide references
  1. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
  2. U.S. Food and Drug Administration.
  3. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805.
  4. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-7.
  5. U.S. Food and Drug Administration.
  6. U.S. Food and Drug Administration.
  7. U.S. Food and Drug Administration.
  8. Reddit participants. Started cjc-1295 ipamorelin stack a couple weeks ago and its making me so tired. (r/Biohackers). Accessed 2026-11-11.
  9. Reddit participants. Cjc-1295/ipamorelin No DAC side effects (r/Peptidesource). Accessed 2026-11-11.
  10. This Is Not Covered - Dr. Ashley Froese. Doctor Explains Your RISK of Cancer From Popular Peptides. Accessed 2026-11-11.
Evidence overview for CJC-1295 Side Effects: Serious Adverse Events